Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1

References

1. Åkerblom L., Hinkula J., Broliden P.-A., Mäkitalo B., Fridberger T., Rosen J., Villacres-Eriksson M., Morein B., Wahren B. 1990; Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 4:953–960
   [Google Scholar]
2. Alexander S., Elder J. H. 1984; Carbohydrate dramatically influences reactivity to viral glycoprotein antigens. Science 226:1328–1330
   [Google Scholar]
3. Arendrup M., Sönnerborg A., Svennerholm B., Åkerblom L., Nielsen C., Clausen H., Olofsson S., Nielsen J. O., Hansen J.-E. S. 1993; Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. Journal of General Virology 74:855–863
   [Google Scholar]
4. Back N. K. T., Smit L., de Jong J.-J., Keulen W., Schutten M., Goudsmit J., Tersmette M. 1994; An N-glycan within the human immunodeficiency virus type 1 gpl20 V3 loop affects virus neutralization. Virology 199:431–438
   [Google Scholar]
5. Balfe P., Simmonds P., Ludlam C. A., Bishop J. O., Leigh Brown A. J. 1990; Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations. Journal of Virology 64:6221–6233
   [Google Scholar]
6. Bosch M. L., Andeweg A. C., Schipper R., Kenter M. 1994; Insertion of N-linked glycosylation sites in the variable regions of the human immunodeficiency virus type 1 surface glycoprotein through AAT triplet reiteration. Journal of Virology 68:7566–7569
   [Google Scholar]
7. Bou-Habib D. C., Roderiquez G., Oravecz T., Berman P. W., Lusso P., Norcross M. A. 1994; Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. Journal of Virology 68:6006–6013
   [Google Scholar]
8. Caust J., Dyall-Smith M. L., Lazdins I., Holmes I. H. 1987; Glycosylation, an important modifier of rotavirus antigenicity. Archives of Virology 96:123–134
   [Google Scholar]
9. Chamat S., Nara P., Berquist L., Whalley A., Morrow W. J. W., Köhler H., Kang C.-Y. 1992; Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Journal of Immunology 149:649–654
   [Google Scholar]
10. Coffin J. M. 1990; Retroviridae and their replication. In Virology 2nd edn, pp 1437–1500 Edited by Fields B. N., Knipe D. M. New York: Raven Press;
    [Google Scholar]
11. Goudsmit J., Debouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J. Jr, Gaxdusek D. C. 1988; Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proceedings of the National Academy of Sciences, USA 85:4478–4482
    [Google Scholar]
12. Gram G. J., Hemming A., Bolmstedt A., Jansson B., Åkerblom L., Nielsen J. O., Hansen J.-E. S. 1994; Identification of an N-linked glycan in the Vl-loop of HIV-1 gpl20 influencing neutralization by anti-V3 antibodies and soluble CD4. Archives of Virology 139:253–261
    [Google Scholar]
13. Hahn B. H., Shaw G. M., Taylor M. E., Redfield R. D., Markham P. D., Salahuddin S. Z., Wong-Staal F., Gallo R. C., Parks E. S., Parks W. P. 1986; Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk of AIDS. Science 232:1548–1553
    [Google Scholar]
14. Hansen J.-E. S., Jansson B., Gram G. J., Clausen H., Nielsen J. O., Olofsson S. 1996; Sensitivity to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop. Archives of Virology (in press)
    [Google Scholar]
15. Harada S., Koyanagi Y., Yamamato N. 1985; Infection of HTLV-III/LAV in HTLV-I-carrying MT-2 and MT-4 cells and application in a plaque assay. Science 229:563–566
    [Google Scholar]
16. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D., Matthews T. J. 1989; Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proceedings of the National Academy of Sciences, USA 86:6768–6772
    [Google Scholar]
17. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P., Holley L. H., Karplus M., Bolognesi D. P., Matthews T. J., Emini E. A., Putney S. D. 1990; Conserved sequence and structural elements in the HIV-principal neutralizing determinant. Science 249:932–935
    [Google Scholar]
18. McKeating J. A., McKnight A., McIntosh K., Clapham P. R., Mulder C., Weiss R. A. 1989; Evaluation of human and simian immunodeficiency virus plaque and neutralization assays. Journal of General Virology 70:3327–3333
    [Google Scholar]
19. Masuda T., Matsushita S., Kuroda M. J., Kannagi M., Takatsuki K., Harada S. 1990; Generation of neutralizationresistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. Journal of Immunology 145:3240–3246
    [Google Scholar]
20. Myers G., Lenroot R. 1992; HIV glycosylation: what does it portend?. AIDS Research and Human Retroviruses 8:1459–1460
    [Google Scholar]
21. Nielsen C. M., Bygbjerg I. C., Vestergaard B. F. 1987; Detection of HIV antigens in eluates of whole blood collected on filter paper [letter]. Lancet i:566–567
    [Google Scholar]
22. Overbaugh J., Rudensey L. M. 1992; Alterations in potential sites for glycosylation predominate evolution of the simian immunodeficiency virus envelope gene in macaques. Journal of Virology 66:5937–5948
    [Google Scholar]
23. Popovic M., Sarnagadharan M. G., Read E., Gallo R. C. 1984; Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497–500
    [Google Scholar]
24. Profy A. T., Saunas P. A., Eckler L. I., Dunlop N. M., Nara P. L., Putney S. D. 1990; Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. Journal of Immunology 144:4641–4647
    [Google Scholar]
25. Reed L. J., Muench H. 1938; A simple method for estimating 50% endpoint. American Journal of Hygiene 27:493–497
    [Google Scholar]
26. Rusche J. R., Javaherian K., McDanal C., Petro J., Lynn D. L., Grimilia R., Langlois R., Gallo R. C., Arthur L. O., Fischinger P. J., Bolognesi D. P., Putney S. D., Matthews T. J. 1988; Antibodies that inhibit fusion of human immunodeficiency virus infected cells bind a 24-amino acid sequence of the viral envelope, gpl20. Proceedings of the National Academy of Sciences, USA 85:3198–3202
    [Google Scholar]
27. Salahuddin S., Markham P., Wong-Staal F., Franchini G., Kalyanaraman V., Gallo R. C. 1983; Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord lymphocytes. Virology 129:51–64
    [Google Scholar]
28. Skehel J. J., Stevens D. J., Daniels R. S., Douglas A. R., Knossow M., Wilson I. A., Wiley D. C. 1984; A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proceedings of the National Academy of Sciences, USA 81:1779–1783
    [Google Scholar]
29. Wolfs T. F. W., de Jong J.-J., van den Berg H., Tunagel J. M. G. H., Krone W. J. A., Goudsmit J. 1990; Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proceedings of the National Academy of Sciences, USA 87:9938–9942
    [Google Scholar]